PMID- 11244573
OWN - NLM
STAT- MEDLINE
DCOM- 20010521
LR  - 20181130
IS  - 1079-9907 (Print)
IS  - 1079-9907 (Linking)
VI  - 21
IP  - 2
DP  - 2001 Feb
TI  - Production of matrix metalloproteinase-9 in CaCO-2 cells in response to 
      inflammatory stimuli.
PG  - 93-8
AB  - Matrix metalloproteinase-9 (MMP-9) may play an important role in the development 
      of inflammatory bowel disease (IBD). However, the cellular source of MMP-9 in the 
      inflamed mucosa of IBD remains unclear. Here we report that MMP-9 mRNA is 
      expressed in CaCO-2 cells, an intestinal epithelial cell line, and that its 
      expression is upregulated by inflammatory stimuli. Stimulation of CaCO-2 cells 
      with interleukin-1beta (IL-1beta) or tumor necrosis factor-alpha (TNF-alpha) led 
      to a dose-dependent increase in expression and secretion of MMP-9. In contrast, 
      bacterial lipopolysaccharide (LPS) failed to induce expression or secretion of 
      MMP-9, suggesting that an inflammatory reaction leading to cytokine release is a 
      necessary step for the induction of MMP-9 release in intestinal epithelial cells. 
      Additional studies show that induction of MMP-9 mRNA peaked at 16 h of IL-1beta 
      stimulation, whereas expression of monocyte chemoattractant protein-1 (MCP-1) and 
      IL-8 both peaked at 3 h of stimulation. Treatment of CaCO-2 cells with 
      rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) 
      agonist, significantly reduced secretion of MMP-9, indicating that agents that 
      activate PPAR-gamma may have therapeutic use in patients with IBD.
FAU - Gan, X
AU  - Gan X
AD  - Department of Lipid Biochemistry, Merck Research Laboratories, Rahway, NJ 07065, 
      USA.
FAU - Wong, B
AU  - Wong B
FAU - Wright, S D
AU  - Wright SD
FAU - Cai, T Q
AU  - Cai TQ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Interferon Cytokine Res
JT  - Journal of interferon & cytokine research : the official journal of the 
      International Society for Interferon and Cytokine Research
JID - 9507088
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-1)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (Thiazoles)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Caco-2 Cells
MH  - Humans
MH  - Inflammation Mediators/pharmacology
MH  - Inflammatory Bowel Diseases/*enzymology/*etiology/genetics
MH  - Interleukin-1/pharmacology
MH  - Lipopolysaccharides/pharmacology
MH  - Matrix Metalloproteinase 9/*biosynthesis/genetics
MH  - RNA, Messenger/genetics/metabolism
MH  - Receptors, Cytoplasmic and Nuclear/agonists
MH  - Rosiglitazone
MH  - Thiazoles/pharmacology
MH  - *Thiazolidinediones
MH  - Transcription Factors/agonists
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - Up-Regulation/drug effects
EDAT- 2001/03/13 10:00
MHDA- 2001/05/25 10:01
CRDT- 2001/03/13 10:00
PHST- 2001/03/13 10:00 [pubmed]
PHST- 2001/05/25 10:01 [medline]
PHST- 2001/03/13 10:00 [entrez]
AID - 10.1089/107999001750069953 [doi]
PST - ppublish
SO  - J Interferon Cytokine Res. 2001 Feb;21(2):93-8. doi: 10.1089/107999001750069953.